10 Best Cheapest Stocks To Invest In Right Now

With college graduation season upon us, it’s again time to take a look at which majors garner the most pay.

For all of the jobs in the Top 30, starting pay was up over last year. Engineering and science occupations continued their stranglehold on the top third of the rankings. For the record, still coming in dead last is Child and Family Studies with a starting salary of $30,300 and a mid-career salary (15 years in) of $37,200.

In 2012, we looked at which degrees were paying the most. This year, as we did in 2013, we drilled down into specific majors using data from payscale.com. Payscale lists 129 majors on its site.

(Check out: 15 Cheapest Colleges With Best Job Value on ThinkAdvisor)

The rankings below are based on data collected from 1,000 universities and include graduates with bachelor’s degrees only. The universities surveyed include 88% of U.S. schools with an enrollment of more than 5,000.

Take a look at the 30 Best Paying College Majors for 2014:

Top 5 Communications Equipment Stocks To Buy Right Now: Raptor Pharmaceutical Corp.(RPTP)

Raptor Pharmaceuticals Corp. operates as a biotechnology company in the United States. The company is dedicated to speeding the delivery of new treatment options to patients by working to improve existing therapeutics through the application of highly specialized drug targeting platforms and formulation expertise. Its clinical stage development products include DR Cysteamine, which is in phase IIb for the treatment of cystinosis; phase IIa for the non-alcoholic steatohepatitis; and phase II for the treatment of Huntington?s disease. Raptor?s clinical-stage products also include Convivia that is in Phase IIa stage for the potential management of acetaldehyde toxicity due to alcohol consumption; and Tezampanel and NGX 426, which completed phase I stage for the treatment of migraine and pain. Its preclinical product candidates comprise HepTide for the treatment of Hepatocellular Carcinoma and Hepatitis; WntTide for the treatment of breast cancer; NeuroTrans for the treatmen t of neurodegenerative diseases; and Tezampanel and NGX 426 for the treatment of Thrombosis and Spasticity Disorder. Raptor Pharmaceuticals Corp. is headquartered in Novato, California.

Advisors' Opinion:

• [By Sean Williams]

  Raptor Pharmaceuticals (NASDAQ: RPTP  ) also gave shareholders something to cheer about when, on Tuesday, the company announced that the Food and Drug Administration had granted Procysbi, its nephropathic cystinosis drug, U.S. orphan drug status. Although FDA-approved drugs are protected by patent for a period of 20 years, the U.S. orphan drug status will keep biosimilar competition from competing against Raptor's Procysbi through April 30, 2020. In addition, on Friday Procysbi received a positive opinion from the European Medicine Agency's panel that the drug be recommended for approval in the EU. However, I'd caution calmer heads prevail here as the total market for the drug is only about 2,000 people worldwide and peak sales estimates in the U.S. are a mere $60 million.

• [By Roberto Pedone]

  One biotechnology player that's starting to trend within range of triggering a big breakout trade is Raptor Pharmaceuticals (RPTP), which has a pipeline that includes both candidates from its proprietary drug targeting platforms and in-licensed and acquired product candidates. This stock is in play with the bulls so far in 2013, with shares up sharply by 151%.

  >>5 Hated Earnings Stocks You Should Love

  If you take a look at the chart for Raptor Pharmaceuticals, you'll notice that stock has been uptrending strong for the last six months, with shares soaring higher from its low of $5.50 to its recent high of $15.29 a share. During that uptrend, shares of RPTP have been consistently making higher lows and higher highs, which is bullish technical price action. That move has now pushed shares of RPTP within range of triggering a big breakout trade.

  Traders should now look for long-biased trades in RPTP if it manages to break out above some near-term overhead resistance levels at $14.99 a share to its 52-week high at $15.29 a share with high volume. Look for a sustained move or close above those levels with volume that hits near or above its three-month average volume of 844,332 shares. If that breakout triggers soon, then RPTP will set up to enter new 52-week-high territory, which is bullish technical price action. Some possible upside targets off that breakout are $18 to $20 a share, or even north of $20 a share.

  Traders can look to buy RPTP off any weakness to anticipate that breakout and simply use a stop that sits right below some key near-term support levels at $13.69 a share or at $13 a share. One can also buy RPTP off strength once it takes out those breakout levels with volume and then simply use a stop that sits a comfortable percentage from your entry point.

• [By Sean Williams]

  Veloci-Raptor time?
  First up is Raptor Pharmaceuticals (NASDAQ: RPTP  ) with Procysbi (previously known as RP-103), its oral delayed and extended-release medication to treat nephropathic cystinosis. In trials, Procysbi proved to be non-inferior to the only other FDA-approved treatment for nephropathic cystinosis, known as Cystagon from Mylan (NASDAQ: MYL  ) .

10 Best Cheapest Stocks To Invest In Right Now: MTS Systems Corporation(MTSC)

MTS Systems Corporation supplies test systems and industrial position sensors in the Americas, Europe, and Asia. The company?s Test segment provides testing solutions, including road simulators for durability simulation; tire performance and rolling resistance measurement systems; moving road-plane systems and balances use for aerodynamics measurements in wind tunnels; systems for the physical characterization of materials, such as ceramics, composites, and steel; systems to test durability and performance of implants, prostheses, and other medical and dental materials and devices. This segment also offers products, systems, and software to perform static and fatigue testing of aircraft and space vehicles; systems for structural engineering, including high force static and dynamic testing; and seismic simulation tables to test the designs of structures and set building codes. In addition, it provides various accessories and spare parts, as well as installation, calibratio n, maintenance, training, and consulting services. This segment serves automobile, truck, motorcycle, motorsports vehicle, construction equipment, agricultural equipment, rail, and off-road vehicle manufacturers and their suppliers, as well as power generation, aerospace, bio-medical, wind energy, structural engineering, and petroleum industries. The company?s Sensors segment manufactures products utilizing magnetostriction technology for manufacturers of mobile equipment, plastic injection molding machines, and wood product processing equipment, as well as to steel mill, fluid power, oil and gas, medical, and alternative energy industries. It also offers products to measure fluid displacement for customers in the process industries. The company sells its products through direct sales organization, and independent representatives and distributors, as well as through the Internet and catalogs. MTS Systems Corporation was founded in 1966 and is headquartered in Eden Prairie, Minnesota.

Advisors' Opinion:

• [By Brian Pacampara]

  Based on the aggregated intelligence of 180,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, road simulator specialist MTS Systems (NASDAQ: MTSC  ) has earned a coveted five-star ranking.

10 Best Cheapest Stocks To Invest In Right Now: Midway Gold Corporation(MDW)

Midway Gold Corp., an exploration stage company, engages in the acquisition, exploration, and development of mineral properties in North America. Its principal properties include the Spring Valley, Midway, Pan, and Gold Rock gold and silver mineral properties located in Nevada; and the Golden Eagle gold mineral property located in Washington. The company was formerly known as Red Emerald Resource Corp. and changed its name to Midway Gold Corp. in July 2002. Midway Gold Corp. was founded in 1996 and is headquartered in Englewood, Colorado.

Advisors' Opinion:

• [By Lisa Levin]

  Midway Gold (NYSE: MDW) shares fell 3.90% to reach a new 52-week low of $0.74. Midway Gold's trailing-twelve-month ROA is -11.16%.

  Posted-In: 52-Week LowsNews Movers & Shakers Intraday Update Markets

10 Best Cheapest Stocks To Invest In Right Now: Golden Minerals Co (AUM)

Golden Minerals Company (Golden Minerals), incorporated March 6, 2009, is a mining company. The Company owns and operates the Velardena and Chicago precious metals mining operations (the Velardena Operations) in the State of Durango, Mexico, the El Quevar advanced exploration property in the province of Salta, Argentina, and a diversified portfolio of precious metals and other mineral exploration properties located in the regions of Mexico and South America.

Velardena Operations

The Velardena Operations consists of two underground mines and two processing plants within the Velardena mining district, which is located in the municipality of Cuencame, in the northeast quadrant of the State of Durango, Mexico, approximately 65 kilometers southwest of the city of Torreon, Coahuila and approximately 140 kilometers northeast of the city of Durango, the capital of the State of Durango. Of the two underground mines consisting the Velardena Operations, the Velardena mine includes three different vein systems, including the Santa Juana, San Juanes and San Mateo systems. The second mine, the Chicago mine, is a producing mine located on the Chicago property approximately two kilometers south of the Velardena property.

The Company owns a 300 ton-per-day flotation sulfide mill situated near the town of Velardena. The mill has fully operational lead, zinc, and pyrite flotation circuits which produce lead, zinc and pyrite concentrates from the sulfide ore. The Company also own a conventional 550 ton-per-day cyanide leach oxide mill with a Merrill Crowe precipitation circuit and new installed flotation circuit, which is located adjacent to its Chicago mine. The mill is used to process oxide and mixed sulfide/oxide material from the Velardena Operations.

El Quevar

The Company's El Quevar silver project is located in the San Antonio de los Cobres municipality, Salta Province, in the altiplano region of northwestern Argentina, approximately 300 kilometers by! road northwest of the city of Salta, the capital city of the province. The El Quevar project is located near Nevado Peak with altitudes at the concessions ranging from 3,800 to 6,130 meters above sea level. The El Quevar project is consists of 32 exploitation concessions. The Company holds 31 of the concessions directly, and the Company controls the Nevado I concession, located approximately four kilometers from the Yaxtche target.

Zacatecas (Mexico)

The Zacatecas Mining District is located in the central part of Mexico, in the Faja de Plata mineral belt. The Company's Zacatecas project surrounds the municipalities of Zacatecas, Veta Grande, Guadalupe, Panuco, and Morelos in the state of Zacatecas, Mexico. The Company owns approximately 195 concessions totaling approximately 8,600 hectares in the Zacatecas project.

San Diego (Mexico)

The San Diego property, located in the State of Durango, Mexico, is situated approximately nine kilometers northeast of the Velardena property and contains the La Cruz-La Rata and El Trovador mines as well as a number of other shallower shafts which were sunk on narrower veins such as the Cantarranas, Montanez and El Jal. During the year ended December 31, 2012, a Phase VI drilling program was completed, which included five drill holes totaling 5,500 meters.

Advisors' Opinion:

• [By Joshi Madhavi]

  The company gets its revenues from two types of fees: management fees which are linked to the assets under management (AUM) and performance fees which can be quite volatile. Over the last five years AUM have increased by around 4% per annum from the low at the end of 2008. However, revenues have decreased by around 7% per annum. Performance fees have held up okay since 2008, but management fees have taken a big hit. Since revenues are dependent on the average AUM over the whole year, let�� look at revenues from 2009 ��they have grown by around 6.5% per annum in this case. Institutional clients are more sticky and stable compared to retail, but the company has not managed to increase AUM from this source substantially over the last five years.

10 Best Cheapest Stocks To Invest In Right Now: Renaissance Oil Corp (ROE)

Renaissance Oil Corp, formerly San Antonio Ventures Inc., is developing a diversified shale and mature fields portfolio for development in Mexico and Spain. The Company is partnered with Grupo SAMCA, a diverse industrial with operations in energy, mining, industrial minerals, agriculture, environmental and various other business lines in Spain. Advisors' Opinion:

• [By Holly LaFon]

  Question: What is your view on Travelers (TRV)�� competitive advantage? How troubling is the huge fixed-income portion of their investment portfolio (in relation to future inflation)? How much do you like Jay Fishman? I really like the fact they are aggressively repurchasing shares and the fact that it is trading at book value, which I estimate to earn around 13% (ROE).

• [By Holly LaFon]

  Investing in small or micro cap funds will be more volatile and loss of principal could be greater than investing in large cap or more diversified funds.Investing in foreign securities, especially in frontier and emerging markets, entails special risks, such as currency fluctuations and political uncertainties, which are described in more detail in the prospectus.For the period ended March 31, 2014, the average annual total returns of the Wasatch International Growth (Trades, Portfolio) Fund for the one-, five- and ten-year periods were 12.71%, 28.72%, and 10.73%, and the returns for the MSCI AC World Ex-U.S.A. Small Cap Index were 16.28%, 21.18%, and 9.31%. Expense ratio: Gross 1.57% / Net 1.57%.Recent stock market performance has caused atypical short-term returns for some asset classes,which may not continue in the future. Fund performance may be subject to substantial short-term changes due to market volatility.Data shows past performance, which is not indicative of future performance. Current performance may be lower or higher than the data quoted. To obtain the most recent month-end performance data available, please click on the ��erformance��tab of the individual fund under the ��ur Funds��section. The Advisor may absorb certain Fund expenses, without which total return would have been lower. Investment returns and principal value will fluctuate and shares, when redeemed, may be worth more or less than their original cost.Wasatch Funds will deduct a 2.00% redemption proceeds fee on Fund shares held 60 days or less. Performance data does not reflect the deduction of fees, including sales charges, or the taxes you would pay on fund distributions or the redemption of fund shares. Fees and taxes, if reflected, would reduce the performance quoted. Wasatch does not charge any sales fees. For more complete information including charges, risks and expenses, read the prospectus carefully.Wasatch Funds are subject to risks, including loss of principal.Over

• [By ovenerio]

  In this article, let麓s see one of the most important financial ratios applying to stockholders, the best measure of performance for a firm's management: the Return on Equity (ROE), and we are going to analyze it in the case of Oracle Corporation (ORCL), the leading provider of enterprise technology solutions, offering software, services and hardware.ROE is calculated as net income applicable to common shares divided by the average book value of common equity: ROE = Net Income / Av. Book ValueA higher ROE is viewed as a positive aspect for the company, but the reason behind it should be examine. From the equation above, we can see that if book value is decreasing more rapidly than net income, the ratio will increase, but this is not good for the firm.Dupont AnalysisThis approach can be used to analyze the ROE. With some algebra we can break down ROE into a function of different ratios. Firstly, we are going to consider the original approach:Original Dupont Equation: Three-Part DupontTaking the ROE equation: ROE = net income / shareholder's equity and multiplying ROE by (revenue / revenue), and rearranging terms we get:ROE = (net income / revenue) * (revenue / shareholder's equity)We now have ROE broken into two parts, the first is net profit margin, and the second is the equity turnover ratio. Now we can expand this by multiplying these terms by (assets / assets), and rearranging we end up with the three-step DuPont equation.ROE = (Net Income / Revenue) * (Revenue / Assets) * (Assets / Shareholder's Equity)This equation for ROE breaks it into three widely used and studied components:ROE = (Net profit margin)* (Asset Turnover) * (Leverage ratio)The first term is what we called previously net profit margin, the second term is asset turnover and the third tem is a financial leverage ratio. If we have a low ROE, one of the following must be true:The firm has a poor profit marginThe firm has a poor asset turnoverThe firm has a little leverageROE (%) 3 StepMay-05May-0

• [By Michael Robinson]

  Separate the signal from the noise: To create real wealth, you have to ignore Wall Street's hype machine and focus on firms with excellent fundamentals. And Jazz certainly has a great foundation. The company has operating margins of 41% and a return on stockholders' equity (ROE) of 31%.

10 Best Cheapest Stocks To Invest In Right Now: Research in Motion Limited(RIMM)

Research In Motion Limited (RIM) designs, manufactures, and markets wireless solutions for the worldwide mobile communications market. The company, through the development of integrated hardware, software, and services, provides platforms and solutions for seamless access to time-sensitive information, including email, phone, short messaging service, and Internet and Intranet-based applications and browsing. Its products and services principally comprise the BlackBerry wireless platform, the RIM Wireless Handheld product line, software development tools, and other software and hardware. The company?s BlackBerry smartphones use wireless, push-based technology that delivers data to mobile users? business and consumer applications. Its BlackBerry smartphone portfolio includes BlackBerry Bold series, the BlackBerry Torch, BlackBerry Curve series, the BlackBerry Style, BlackBerry Storm series, the BlackBerry Tour, BlackBerry Pearl series, and the BlackBerry PlayBook tablet. T he company?s BlackBerry enterprise solutions comprise BlackBerry enterprise server, BlackBerry enterprise server express, BlackBerry mobile voice system, and hosted BlackBerry services. Its technology also enables third party developers and manufacturers to enhance their products and services through software development kits, wireless connectivity to data, and third-party support programs. In addition, the company offers BlackBerry technical support services, non-warranty repairs, and nonrecurring engineering services. Further, it provides BlackBerry App World that offers BlackBerry smartphone users an electronic catalogue that aids in the discovery and download/purchase of applications directly from their BlackBerry smartphone. The company markets and sells its BlackBerry wireless solutions primarily through global wireless communications carriers, and third party distribution channels. Research In Motion Limited was founded in 1984 and is headquartered in Waterloo, Canad a.

Advisors' Opinion:

• [By Trustamind]

  Technology is disruptive. It changes everyone�� daily life. But it also may cause unpleasant financial consequences to investors. Technology brings dramatic economic growth which is, unfortunately, less predictable. In Buffett�� own words when asked in the interview if he would buy other tech companies: �� look at everything but most things I decide I can't figure out their future.��For some examples, just look at Research In Motion (RIMM) versus Apple (AAPL), Yahoo! (YHOO) versus Google (GOOG), and Kodak versus all the other digital camera makers. The last one is especially ironic because it is Kodak that invented the digital camera in the first place.

• [By Matthew Indyke and Brian Zen]

  Klarman said the following to investors in his Baupost letter earlier this year: ��ur disciplined risk aversion throughout 2011 enabled us to avoid dangerous temptations and remain focused on investments in our areas of strength and competitive advantage.��Competitive advantage comes down to two questions. Can the company raise prices for their products while maintaining sales in a competitive environment? Can it continue to retain customers as the business undergoes operational and technological changes? One aspect for investors to keep in mind is that of technological change, a constant threat to industries like retail stores and mobile communications. Best Buy (BBY) used to be the go-to place where customers could shop for electronic appliances but internet retail took that away. RIM (RIMM) used to be a model company that produced phones for email on-the-go but competitors like Apple (AAPL) and Google (GOOG) upped the ante and took away the value of RIM�� products. These kinds of circumstances show that keeping up with trends on a regular basis is a vital part of bottom-up investing.

• [By Holly LaFon]

  If an idea doubles within a year, the contestant will win more. This month, GuruFocus is awarding author Jean-Francois Nobert (Ecotycoon) $1,000 for his idea, Research In Motion (RIMM), which doubled since he submitted in July.

10 Best Cheapest Stocks To Invest In Right Now: BioMarin Pharmaceutical Inc.(BMRN)

BioMarin Pharmaceutical Inc. develops and commercializes biopharmaceuticals for serious diseases and medical conditions in the United States, Europe, Latin America, and rest of the world. The company?s commercial products include Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase enzyme used for the treatment of mucopolysaccharidosis (MPS) VI; Kuvan, a proprietary synthetic oral form of 6R-BH4 used to treat patients with phenylketonuria (PKU), a metabolic disease; Aldurazyme used for the treatment of mucopolysaccharidosis I, a genetic disease; and Firdapse used to treat Lambert Eaton Myasthenic Syndrome, an autoimmune disease. It develops GALNS, an enzyme replacement therapy for the treatment of MPS IVA, a lysosomal storage disorder; PEG-PAL, an enzyme substitution therapy that is under Phase II clinical trial to treat PKU; BMN-673, a Phase I/II clinical trial product for the treatment of cancer; BMN-701, an enzyme replacement therapy, which is under Phase I/II clinical trials for Pompe disease, a glycogen storage disorder; and BMN-111, a peptide therapeutic that is under Phase I clinical trial for the treatment of achondroplasia. The company sells its Naglazyme, Kuvan, and Firdapse products to specialty pharmacies and end-users, such as hospitals and foreign government agencies, which act as retailers; and Naglazyme products to distributors and pharmaceutical wholesalers. It has a collaboration agreement with Genzyme Corporation for the manufacture of Aldurazyme; and an agreement with Merck Serono S.A. for the further development and commercialization of Kuvan and other products containing 6R-BH4 and PEG-PAL for PKU. BioMarin Pharmaceutical Inc. was founded in 1996 and is headquartered in Novato, California.

Advisors' Opinion:

• [By Monica Gerson]

  BioMarin Pharmaceutical (NASDAQ: BMRN) shares moved up 1.48% to $78.64. The volume of BioMarin Pharmaceutical shares traded was 966% higher than normal. BioMarin shares jumped on Roche Holding (OTC: RHHBY) takeover report..

• [By MONEYMORNING.COM]

  There is no crystal ball that's 100% accurate when experimental drugs are concerned, but here are some telling questions that can narrow your search.

  Questions to Answer Before You Buy In Does the drug fulfill an unmet need?
  
  Alexion Pharmaceuticals Inc.'s (Nasdaq: ALXN) Soliris (eculizumab) is the only drug approved to treat paroxysmal nocturnal hemoglobinuria (PNH), an extremely rare, lethal blood disorder. It is also the only therapy approved to treat atypical hemolytic uremic syndrome (aHUS), a genetic condition that can result in sudden and progressive damage to vital organs, leading to stroke, heart attack, and kidney failure. Five years ago, ALXN shares were selling for about $18.50. They recently hit a high of $180.51 - thanks to Soliris, and Soliris alone. Is it a "breakthrough" drug?
  
  A "Breakthrough Therapy" (BT) is actually a designation awarded by the FDA for a drug that "...is intended alone or in combination with one or more other drugs to treat a serious or life-threatening disease or condition and [has] preliminary clinical evidence [that] indicates the drug may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development." In 2012, the FDA granted Roche/Genetech's Gasyva a BT designation and then approved it for marketing in 2013. It treats chronic lymphocytic leukemia (CLL) and is expected to be a big blockbuster - as are the other three breakthrough therapies that were approved last year. Can its market produce blockbuster income?
  
  This can mean a huge market, such as patients with high cholesterol - think Pfizer Inc.'s (NYSE: PFE) Lipitor (atorvastatin calcium), the bestselling drug of all time - or a small market that will pay for highly priced orphan drugs for rare diseases. BioMarin Pharmaceutical Inc. (Nasdaq: BMRN), a company that specializes in the
• [By George Budwell]

  Will BioMarin be the next orphan drugmaker to be bought out?
  Over the last decade, BioMarin Pharmaceutical (NASDAQ: BMRN  ) has become one of the top orphan drug specialists, making it a frequent visitor to the buyout rumor mill. Roche (NASDAQOTH: RHHBY  ) was previously named as an interested party, but the company's CEO squashed that rumor, saying BioMarin was too expensive.

• [By Sean Williams]

  BioMarin Pharmaceuticals (NASDAQ: BMRN  )
  BioMarin might as well be considered a long lost sibling of Alexion, since they are both focused on developing rare orphan drugs which have practically no competition and hefty annual price tags, often in six-figures. However, whereas Alexion is profitable, BioMarin has some "'splaining to do," as Desi Arnaz used to say. Estimates in the upcoming quarter call for sales growth of just 8% to $134 million with losses expected to widen to $0.29 per share. Naglazyme's 1% sales increase last quarter didn't impress at all, so it'll need Aldurazyme to really step up if it hopes to maintain its frothy valuation.